Skip to main content
Top
Published in: Diabetology International 4/2016

01-12-2016 | Report of the committee

New glycemic targets for patients with diabetes from the Japan Diabetes Society

Authors: Eiichi Araki, Masakazu Haneda, Masato Kasuga, Takeshi Nishikawa, Tatsuya Kondo, Kohjiro Ueki, Takashi Kadowaki

Published in: Diabetology International | Issue 4/2016

Login to get access

Abstract

In the “Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013,” a new concept of glycemic control in patients with diabetes in Japan has been declared from the Japan Diabetes Society. The main objective value of HbA1c was set to <7% from the perspective of preventing microvascular complications. On the other hand, the objective in cases where objectives can be attained by appropriate dietary or exercise therapy or during pharmacotherapy without the occurrence of side effects such as hypoglycemia was set to <6%, and the objective in cases where intensification of treatment was considered difficult because of the side effects such as hypoglycemia or for other reasons was set to <8%. Treatment objectives should be established individually, considering the age, duration of disease, organ damage, risk of hypoglycemia, support structure, etc.
Literature
1.
go back to reference Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.CrossRefPubMed Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.CrossRefPubMed
2.
go back to reference Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.CrossRefPubMed Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.CrossRefPubMed
3.
go back to reference Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRefPubMed Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRefPubMed
4.
go back to reference Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.CrossRefPubMed Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.CrossRefPubMed
5.
go back to reference Gerstein HC, Miller ME, Byington BP, Action to control cardiovascular risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefPubMed Gerstein HC, Miller ME, Byington BP, Action to control cardiovascular risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefPubMed
6.
go back to reference Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.CrossRefPubMedPubMedCentral Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.CrossRefPubMedPubMedCentral
7.
go back to reference Ito C, Maeda R, Ishida S, et al. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract. 2000;50:225–30.CrossRefPubMed Ito C, Maeda R, Ishida S, et al. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract. 2000;50:225–30.CrossRefPubMed
8.
go back to reference Yamamoto-Honda R, Kitazato H, Hashimoto S, et al. Distribution of blood glucose and the correlation between blood glucose and hemoglobin A1c levels in diabetic outpatients. Endocr J. 2008;55:913–23.CrossRefPubMed Yamamoto-Honda R, Kitazato H, Hashimoto S, et al. Distribution of blood glucose and the correlation between blood glucose and hemoglobin A1c levels in diabetic outpatients. Endocr J. 2008;55:913–23.CrossRefPubMed
9.
go back to reference Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.CrossRefPubMedPubMedCentral Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.CrossRefPubMedPubMedCentral
10.
go back to reference The Diabetes Control and Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289–98.CrossRef The Diabetes Control and Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289–98.CrossRef
11.
go back to reference United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
12.
go back to reference Balkau B, Hu G, Qiao Q, DECODE Study Group; European Diabetes Epidemiology Group, et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia. 2004;47:2118–28.CrossRefPubMed Balkau B, Hu G, Qiao Q, DECODE Study Group; European Diabetes Epidemiology Group, et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia. 2004;47:2118–28.CrossRefPubMed
Metadata
Title
New glycemic targets for patients with diabetes from the Japan Diabetes Society
Authors
Eiichi Araki
Masakazu Haneda
Masato Kasuga
Takeshi Nishikawa
Tatsuya Kondo
Kohjiro Ueki
Takashi Kadowaki
Publication date
01-12-2016
Publisher
Springer Japan
Published in
Diabetology International / Issue 4/2016
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-016-0297-4

Other articles of this Issue 4/2016

Diabetology International 4/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.